Recombinant adeno-associated virus vectors have become the dominant platform for in vivo gene therapy, with more than 700 active clinical and preclinical programs now spanning neurological, ophthalmological, neuromuscular, and metabolic disease. Yet for all this AAV therapy momentum, the upstream manufacturing process has remained stubbornly inefficient. Most commercial and clinical AAV is still produced by transiently transfecting HEK293 cells with three separate plasmids, a method first established more than two decades ago and never originally designed for the batch sizes, regulatory scrutiny, or cost pressures of a now-crowded gene therapy pipeline.

Plasmid cost alone can account for a substantial share of cost-of-goods at commercial scale, and variability in transfection efficiency from lot to lot remains a leading cause of batch failure. Between 2023 and 2026, three interconnected areas of innovation, namely transfection reagents, stable producer cell lines, and plasmid architecture have begun to meaningfully reshape this picture, promising not just incremental efficiency gains but a fundamentally different manufacturing paradigm.

Transfection Reagents: Squeezing More Out of Triple Transfection

Even as the industry works toward plasmid-free production, triple transfection remains the workhorse method behind majority of the approved gene therapy products, which means reagent performance still matters enormously in the near term. Linear polyethylenimine, or generic PEI, has long dominated this space because it is inexpensive, scalable and familiar in HEK293 transient transfection. For example, Kyfora Bio supplies PEIMax, a high molecular weight linear PEI formulation widely used in academic and industrial HEK293 transfection workflows. However, generic PEI workflows require careful optimization of DNA:reagent ratio, cell density, complexation time, media and harvest timing. Therefore, the market has moved beyond generic PEI toward purpose-built, GMP-grade formulations. Supplier-optimized reagents have emerged to reduce some of this development burden. Table 1 outlines the top AAV transfection reagents and kits currently on the market.

Table 1. AAV transfection reagents and kits on the market

These supplier platforms may be useful in process development, but their performance should be treated as process- and serotype-dependent until verified with the developer’s own construct, capsid and scale.

Stable Producer Cell Lines: The Future Manufacturing Position

Reagent optimization is widely viewed as a bridge technology rather than an end state. The more consequential trend is the shift toward stable, inducible producer cell lines that do away with per-batch plasmid transfection altogether, since every batch that requires fresh GMP plasmid is exposed to lot-to-lot plasmid quality variability and a substantial line item in cost-of-goods.

The field has moved through consecutive evolutions. Second-generation packaging lines still require transfection of the gene of interest into cells that already stably express Rep, Cap, and helper functions, while third-generation fully stable producer lines integrate everything, including the transgene itself, into the host genome and require nothing more than an induction signal to begin production. Stable producer cell lines, though, are only considered for locked-down, GMP processes at this time, and transfection remains the common approach during development. Other than for standard helper plasmids, a variety and customization of packaging and transgene plasmids is typically required at the early stages.

That said, the ELEVECTA™ platform, originally developed by CEVEC and acquired by Cytiva in 2022, is one of the more visible examples of a stable, helper-virus-free AAV producer-cell-line technology. Cytiva and CEVEC materials describe the platform as integrating the functions required for AAV production into the producer-cell genome and avoiding both transient transfection and helper virus at production scale. ELEVECTA™ integrates Rep, Cap, helper genes, and the gene of interest directly into HEK293 cells under tetracycline-inducible control, enabling scale-up in stirred-tank bioreactors with high batch-to-batch consistency and no plasmid or helper virus required at the point of production. Asimov, a synthetic biology company based in Boston, entered this space in October 2025 with its AAV Edge system, promising fully stable, suspension-adapted, clonal producer cell lines within roughly twenty weeks leveraging an AI-based design suite.

These transitions represent a significant direction for the field, but not proof that stable cell lines will rapidly replace transient transfection for all products at all phases of development. Clonal stability, product-specific yield, genome integrity, capsid quality, induction control, regulatory comparability and development timelines remain critical considerations.

On the other hand, the baculovirus and Sf9 insect cell expression system remains a relevant alternative for select serotypes, and continues to underpin commercial products such as uniQure’s Hemgenix, an AAV5-based hemophilia B therapy. Their advantages include scalability and avoidance of HEK293 triple transfection but challenges include baculovirus genetic instability, baculovirus-related DNA impurities, capsid-quality differences and non-mammalian post translational modifications.

Emerging Plasmid Architectures: 3 to 2…to 1?

While transient transfection persists as the development platform of choice, plasmid architecture is being redesigned to cut down workflows associated with the conventional three-plasmid systems. These systems also carries a quality risk in that fragments of plasmid backbone DNA can be inadvertently packaged into capsids as DNA impurities, contributing to the burden that downstream purification must remove. Two-plasmid configurations such as the pDG architecture, which consolidates Rep, Cap, and helper genes onto one large plasmid, offer partial relief while allowing for adaptability with the transgene.

The more striking development has been the emergence of genuine single-plasmid, all-in-one systems. Synplogen (Kobe, JP) has developed the All-in-One Plasmid™, which uses a proprietary bacterial assembly method known as OGAB to stitch the adenovirus helper genes, the AAV rep and cap genes, and the full transgene cassette onto a single compact plasmid construct, reportedly matching the titers achieved by conventional triple transfection while substantially simplifying plasmid procurement, quality control, and lead times.

Similarly, AAVone® by AAVner Gene (Rockville, MD) offers a single plasmid backbone, with the notable advantage of markedly fewer DNA backbone impurities compared to triple transfection. In the same manner as stable producer cell lines, though, single-plasmid systems are not yet “plug and play”. For example, Aldevron, based in North Dakota and now part of Danaher, remains one of the most established suppliers of GMP-grade plasmid DNA for developers who have not yet adopted single-plasmid systems.

Conclusion

The most important upstream trend is therefore not a single reagent or cell line, but a gradual move from current, plasmid-heavy processes toward more efficient production platforms. In the near term, improved transfection systems remain relevant because many clinical and commercial workflows still use transient transfection. In the longer term, stable packaging and producer cell lines are being developed to reduce batch-to-batch variability and dependence on large quantities of costly GMP plasmid DNA. Therefore, AAV and plasmid CDMOs must look to in-license, acquire or support these novel upstream platforms in the near term to stay ahead of competition or be prepared to serve broad disease AAV processes with efficient upstream components.

Are you interested in gaining deeper insights into AAV development and manufacturing trends? 

Our bioprocess strategy and product-market fit capabilities may be right for you.  Reach out for a consultation.

References:

  1. Kowshik, N. C. S. S., & Singh, P. (2025). Advancing AAV vector manufacturing: Challenges, innovations, and future directions for gene therapy. Frontiers in Molecular Medicine, 5, 1709095. https://doi.org/10.3389/fmmed.2025.1709095
  2. Park et al., (2025) Viral vector-based gene therapies in the clinic: An update, Bioeng Transl Med. 2026;11:e70106. https://doi.org/10.1002/btm2.70106
  3. Stone, D., Mietzsch, M., & Ronzitti, G. (2025). Advancing AAV technology: From capsid design to scalable manufacturing. Molecular Therapy Methods & Clinical Development, 33, 101477. https://doi.org/10.1016/j.omtm.2025.101477
  4. Polysciences. (2026). Polyethylenimine “Max” (PEI MAX), high-potency linear PEI product information. Supplier literature. https://polysciences.com
  5. Polyplus, part of Sartorius. (2025). FectoVIR-AAV: Industrial-scale AAV production transfection reagent. Product Specifications. https://www.polyplus-sartorius.com/fectovir-aav-gmp
  6. Polyplus/Sartorius. (2020). FectoVIR-AAV: a giant step for AAV large-scale manufacturing. Cell & Gene Therapy Insights / supplier-sponsored technical article.
  7. Polyplus, part of Sartorius. (2023). PEIpro GMP transfection reagent for AAV and lentiviral vector production. Product Specifications.
  8. Mirus Bio. (2025). TransIT-AAViator transfection system with RevIT AAV Enhancer. Technical Product Datasheet. https://www.mirusbio.com
  9. Thermo Fisher Scientific. (2022). CTS AAV-MAX Helper-Free AAV Production System user guide, MAN0026650. Supplier technical manual. https://www.thermofisher.com
  10. Merten, O.-W. (2024). Development of stable packaging and producer cell lines for the production of AAV vectors. Microorganisms, 12(2), 384. https://doi.org/10.3390/microorganisms12020384
  11. Cytiva. (2022, October 6). Cytiva strengthens cell line development with CEVEC acquisition. Press release. https://www.cytivalifesciences.com
  12. CEVEC/Cytiva. (2021). CEVEC and UCB agreement for ELEVECTA technology. Supplier/platform information. https://www.cytivalifesciences.com
  13. Asimov. (2025, October 6). Asimov launches AAV Edge stable producer system. Press Release. https://www.asimov.com
  14. Fu, Q., et al. (2023). Critical challenges and advances in recombinant adeno-associated virus manufacturing. Biotechnology and Bioengineering. 2023 Sep;120(9):2601-2621. doi: 10.1002/bit.28412. Epub 2023 May 1
  15. Yang, R., et al. (2025). AAVone: A cost-effective, single-plasmid solution for efficient AAV production with reduced DNA impurities. Molecular Therapy Nucleic Acids, 36(2), 102563. https://doi.org/10.1016/j.omtn.2025.102563
  16. Synplogen Co., Ltd. (2025). All-in-One Plasmid technology overview. https://www.synplogen.com/en/technology/